News ArchivesRead News
Parkinsons Disease Patches
Thursday February 25, 2010
Parkinson's Disease Society - As a good method of treatment, Parkinson’s disease patch is being developed for treating Parkinson’s disease. This is being developed as a good method of treating it orally. The need to develop a skin patch for Parkinson’s existed, due to the digestive tract of people affected by the disease.
Skin patches are available for smoking cessation, heart problems, and pain control. A major research is going on for exploring new ways of treatment except oral medicines, of Parkinson’s.
The silicon patch that is being used in the clinical trials have Dopamine agonist , a drug commonly used to reduce the symptoms and help people lead a more normal life. ‘Neupro’ is the first trans-dermal patch that has been approved to treat symptoms of Parkinson’s disease.
The main symptoms of Parkinson’s include memory loss, decrease of cognitive skills, dementia. As it is a disorder of the central nervous system, motor skills are lost over time. These Parkinson’s disease patch medicines help in prolonging normal activity and suppressing the symptoms of the disease.
The main symptoms of this disease include stiffness and tremors in the limbs which is due to the reduction of Dopamine, chemical in the brain which controls movement in the body. Dopamine agonists clone dopamine and also stimulate the cells of the brain, just the way the normal chemical reacts.
Another Parkinsons disease patch that has been marketed is an active ingredient Rotigotine, which is a Dopamine receptor delivered through a skin patch. It is applied once to the skin and releases Ritigotine throughout 24 hours. Every day the patch needs to be changed. It is delivered to maintain stable rotigotine plasma in concentration level. The oral Dopamine agonists come in multiple doses but a patch is more effective and easy.
Recent NewsOct 18 - Brain disconnections may contribute to Parkinson's hallucinations
Oct 18 - Fighting Parkinson's disease through dance
Oct 17 - Scientists Identify Structure of PINK1, Key Parkinson’s-protective Protein
Oct 17 - Diabetes drug cuts Parkinson's risk by 28 percent, study finds
Oct 10 - Advances in Brain Pacemaker Reduces Tremors, Helps Parkinson's Sufferers Live a More Normal Life
Oct 10 - Medical History Could Help Predict Parkinson's Disease Risk Long Before Diagnosis
Oct 3 - Changes in Olfactory Bulb Explain Loss of Smell in Early Stages of Parkinson’s Disease, Study Finds
Oct 3 - Sleep Disturbances May Worsen Motor Symptoms in Parkinson’s Disease, Study Suggests
Sep 12 - Australian Researchers Develop New Diagnostic Tool to Spot Early Signs of Parkinson’s
Sep 11 - GeneFo Webinar to Focus on Using Humor to Manage Parkinson’s Disease
Sep 6 - Parkinson’s and the ‘D’ word
Sep 6 - Compounds in Asthma Drugs Might Be Used as Parkinson’s Treatment
Sep 5 - AstraZeneca Joins Takeda, Berg to Advance Development of Parkinson’s Disease Therapies
Sep 1 - Stem Cell Transplant Trial in Parkinson’s Patients Planned After Test in Japan Succeeds in Monkeys
Sep 1 - Titan to Start Phase 1/2 Study of Subdermal Implant to Deliver Requip to Parkinson’s Patients
Aug 30 - FDA Refuses Acorda’s Inbrija New Drug Application Due to Manufacturing Questions
Aug 23 - Support Groups: Are They for You?
Aug 22 - Internet Visits with Parkinson’s Specialist Can Be as Effective as In-person Visits, Trial Finds
Aug 21 - Cavion’s New CMO to Lead Cav3 Platform Development for Neurological Diseases
Aug 15 - Singing Helps Early-stage Parkinson’s Patients Retain Speech, Respiratory Control, Studies Show